title: Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration.
abstract: BACKGROUND
  CSF concentrations of tau and beta-amyloid protein-42 (Abeta42) have been extensively studied in AD. Few data are available concerning CSF levels of both proteins in patients with frontotemporal degeneration (FTD).
  
  
  METHODS
  The authors investigated CSF tau and Abeta42 concentrations in 34 patients with FTD, 74 patients with AD, and 40 cognitively healthy control subjects. CSF levels of tau and Abeta42 were measured by ELISA. With use of receiver operating characteristic-derived cutoff points and linear discrimination lines, the diagnostic sensitivity and specificity of both markers were determined.
  
  
  RESULTS
  CSF tau concentrations were significantly higher in FTD than in control subjects but were significantly lower than in AD. CSF Abeta42 levels were significantly lower in FTD than in control subjects but were significantly higher than in AD. In subjects with FTD, neither tau nor Abeta42 levels correlated with the severity of dementia. The best discrimination between the diagnostic groups was obtained by simultaneous measurement of tau and Abeta42, yielding a sensitivity of 90% at a specificity of 77% (FTD vs controls) and a sensitivity of 85% at a specificity of 85% (FTD vs AD).
  
  
  CONCLUSIONS
  In FTD, CSF levels of tau are elevated and Abeta42 levels are decreased. With use of these markers, subjects with FTD can be distinguished from control subjects and from patients with AD with reasonable accuracy.
authors.affiliation: Neurochemistry and Neurogenetics Laboratory, Department of Psychiatry and Psychotherapy, Technische Universität München, Ismaningerstrasse 22, 81675 Munich, Germany. m.riemenschneider@lrz.tu-muenchen.de
authors.forename: M
authors.initials: M
authors.lastname: Riemenschneider
authors.forename: S
authors.initials: S
authors.lastname: Wagenpfeil
authors.forename: J
authors.initials: J
authors.lastname: Diehl
authors.forename: N
authors.initials: N
authors.lastname: Lautenschlager
authors.forename: T
authors.initials: T
authors.lastname: Theml
authors.forename: B
authors.initials: B
authors.lastname: Heldmann
authors.forename: A
authors.initials: A
authors.lastname: Drzezga
authors.forename: T
authors.initials: T
authors.lastname: Jahn
authors.forename: H
authors.initials: H
authors.lastname: Förstl
authors.forename: A
authors.initials: A
authors.lastname: Kurz
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000473:pathology; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D015415:Biomarkers; D003704:Dementia / Q000134:cerebrospinal fluid* / Q000473:pathology; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000134:cerebrospinal fluid*; D058225:Plaque, Amyloid / Q000473:pathology; D012680:Sensitivity and Specificity; D016875:tau Proteins / Q000134:cerebrospinal fluid*
chemical_list: D016229:Amyloid beta-Peptides; D015415:Biomarkers; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D016875:tau Proteins